Malaysia
Search
Sign In
Change Password
Points
Sign Out
Top Medical News
Ambulatory hypertension appears to be prevalent in children with sickle cell disease, according to a recent study.
Dr Jarrod Lee, a gastroenterologist and advanced endoscopist at gutCARE, Singapore, shares his insights with Pearl Toh on diagnosing and managing diarrhoea in the primary care setting.
Any change in corneal shape after use of soft contact lenses does not appear to have significant effects on biometry results, according to a recent UK study.
Segmentectomy and lobectomy confer similar overall survival (OS) and lung cancer-specific survival (LCSS) among patients with primary nonsmall cell lung cancer (NSCLC) of ≤20 mm without lymph node or distant metastasis, a recent study has shown.
Among children with juvenile idiopathic arthritis, the risk of developing uveitis is not greater in those treated with etanercept than in those receiving methotrexate, according to a study presented at the European League Against Rheumatism (EULAR) 2018 Congress.
Spironolactone appears to have no therapeutic value in patients with hypertrophic cardiomyopathy, a recent prospective trial has found.
Fibromyalgia occurs commonly in patients with rheumatoid arthritis, axial spondyloarthritis and psoriatic arthritis, with disease activity seemingly greater in the presence of fibromyalgia, a study reports.
Special Reports
There is an increasing number of studies that shed light on the importance of our gut microbiota. Probiotics are live microorganisms that confer health benefits on the host when administered in adequate amounts. With new data emerging about their proposed benefits in maintaining intestinal health, probiotics continue to gain popularity amongst consumers.
The medical field has advanced in leaps and bounds. Along with it comes changes in the way we deal with patients or diseases. However, the fundamentals of medicine, namely patient-centred care can sometimes be sidelined in this age and among the aspects that suffer along with it are the high value of a patient’s own blood and the autonomy over his or her own body.
At the recent ‘Reinforced for the Glycaemic Challenge’ symposium held at Shangri-la Hotel, Kuala Lumpur, Associate Professor Dr Alexander Tan, Professor Dr Chee Kok Han and Dr Chan Siew Pheng shared their insights into the importance of achieving glycaemic control in patients with type 2 diabetes mellitus (T2DM), while simultaneously providing them with cardiovascular protection.
At the recent American Society of Haematology Annual Meeting 2017, Professor François-Xavier Mahon reviewed recent studies related to tyrosine kinase inhibitor (TKI) cessation in patients with chronic myeloid leukaemia (CML) who have achieved sustained deep molecular response (DMR).
Multiple sclerosis (MS) is one of the most common neurological disorders – affecting over 2.3 million people globally – and it is the leading cause of nontraumatic disability in young adults. However,the availability of supportive resources and services for people with MS is scarce in many regions of the world. In Malaysia, the prevalence of MS is estimated at 2-3/100,000; the current Malaysian clinical practice guidelines on the management of MS recommend disease modifying agents, such as interferon-β and teriflunomide, as first-line therapeutic agents. In this article, Dr Singer - in partnership with Sanofi and the Malaysian Society of Neurosciences - shares his insights into managing MS dynamically, highlighting the importance of early intervention in improving patient outcomes.
Globally, one in four people will be affected by psychiatric or neurological disorders during their lifetime.1 With an estimated affected population of 450 million people, mental disorders are among the leading causes of ill-health and disability worldwide.1 At the recent Lundbeck Neuroscience Symposium held at Hilton Kota Kinabalu from 3–5 November 2017, three renowned key opinion leaders from the field of psychiatry shared their insights into the optimal management of bipolar disorder and schizophrenia.
At a recent Menarini-sponsored symposium held during the 47th Annual Scientific Meeting of the Malaysian Orthopaedic Association at Kuala Lumpur Convention Centre, Dr Magdi Hanna spoke on the importance of effective postoperative pain management, highlighting the role of multimodal combination therapy in improving treatment outcomes.
Conference Reports
A combined regimen of obinutuzumab (a type II anti-CD20 antibody) and chlorambucil shows significant long-term survival benefit over rituximab plus chlorambucil or chlorambucil alone in patients with chronic lymphocytic leukaemia (CLL) and comorbidities who have not been treated previously, according to the final analysis of the CLL11* study presented at EHA 2018.
The selective cannabinoid receptor type 2 agonist lenabasum exhibited an acceptable safety profile while improving outcomes in patients with diffuse cutaneous systemic sclerosis, according to results of a phase II study.
Analysis of pooled data from three phase III trials (SPIRIT-P1, -P2 and -P3) reveals that ixekizumab (IXE), a high affinity monoclonal antibody that selectively targets interleukin-17A, is a safe treatment for patients with active psoriatic arthritis (PsA), according to a study presented at the Annual European Congress of Rheumatology by the European League Against Rheumatism (EULAR 2018).
Diacerein appears to be more effective than glucosamine plus chondroitin for patients with mild-to-moderate knee osteoarthritis , according to a study presented at the 2018 Annual European Congress of Rheumatology (EULAR 2018).
Adjusting treatment strategy based on results of a PET* scan performed after two cycles of escalated BEACOPP** potentially reduces exposure to toxicity and has comparable outcomes to a standard treatment regimen in patients with advanced Hodgkin lymphoma, according to the final analysis of the phase III AHL 2011 LYSA*** trial presented at EHA 2018.
Treatment with oral thrombopoietin receptor agonist eltrombopag leads to similar platelet counts in patients with chronic immune thrombocytopaenia (cITP) and persistent (per)ITP, according to the results of phase III (EXTEND) and IV studies presented at the 23rd Congress of the European Hematology Association (EHA 2018) held in Stockholm, Sweden.
A treatment regimen combining daratumumab plus bortezomib, melphalan and prednisone markedly extends progression-free survival in patients with multiple myeloma, inducing deep responses and demonstrating acceptable tolerability regardless of baseline renal function, according to the results of the phase III ALCYONE study.
Multimedia
